MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

NASDAQ:MDGL • US5588681057

440 USD
+2.21 (+0.5%)
At close: Feb 24, 2026
440 USD
0 (0%)
After Hours: 2/24/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

MDGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. MDGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, MDGL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • MDGL had negative earnings in the past year.
  • In the past year MDGL has reported a negative cash flow from operations.
  • In the past 5 years MDGL always reported negative net income.
  • In the past 5 years MDGL always reported negative operating cash flow.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • MDGL has a Return On Assets of -22.89%. This is in the better half of the industry: MDGL outperforms 73.70% of its industry peers.
  • MDGL has a Return On Equity of -47.83%. This is in the better half of the industry: MDGL outperforms 67.18% of its industry peers.
Industry RankSector Rank
ROA -22.89%
ROE -47.83%
ROIC N/A
ROA(3y)-41.97%
ROA(5y)-59.17%
ROE(3y)-67.26%
ROE(5y)-94.94%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100

1.3 Margins

  • Looking at the Gross Margin, with a value of 94.14%, MDGL belongs to the top of the industry, outperforming 95.20% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for MDGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MDGL has more shares outstanding than it did 1 year ago.
  • MDGL has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MDGL has a worse debt to assets ratio.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 7.62 indicates that MDGL is not in any danger for bankruptcy at the moment.
  • MDGL's Altman-Z score of 7.62 is fine compared to the rest of the industry. MDGL outperforms 78.50% of its industry peers.
  • MDGL has a Debt/Equity ratio of 0.56. This is a neutral value indicating MDGL is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.56, MDGL is not doing good in the industry: 70.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z 7.62
ROIC/WACCN/A
WACC8.56%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • MDGL has a Current Ratio of 4.01. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
  • MDGL has a Current ratio of 4.01. This is comparable to the rest of the industry: MDGL outperforms 47.79% of its industry peers.
  • A Quick Ratio of 3.77 indicates that MDGL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.77, MDGL is in line with its industry, outperforming 47.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.01
Quick Ratio 3.77
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.33% over the past year.
  • Looking at the last year, MDGL shows a very strong growth in Revenue. The Revenue has grown by 432.05%.
EPS 1Y (TTM)42.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.17%
Revenue 1Y (TTM)432.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%210.77%

3.2 Future

  • MDGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.42% yearly.
  • Based on estimates for the next years, MDGL will show a very strong growth in Revenue. The Revenue will grow by 38.52% on average per year.
EPS Next Y108.25%
EPS Next 2Y84.4%
EPS Next 3Y70.98%
EPS Next 5Y51.42%
Revenue Next Year53.11%
Revenue Next 2Y49.37%
Revenue Next 3Y45.61%
Revenue Next 5Y38.52%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 50 100 150

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 418.19 indicates a quite expensive valuation of MDGL.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MDGL indicates a rather cheap valuation: MDGL is cheaper than 86.95% of the companies listed in the same industry.
  • MDGL is valuated expensively when we compare the Price/Forward Earnings ratio to 28.01, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 418.19
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300 400

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as MDGL's earnings are expected to grow with 70.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y84.4%
EPS Next 3Y70.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MDGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (2/24/2026, 8:00:01 PM)

After market: 440 0 (0%)

440

+2.21 (+0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-29
Inst Owners96.8%
Inst Owner Change-1.11%
Ins Owners1.13%
Ins Owner Change2.42%
Market Cap9.99B
Revenue(TTM)958.40M
Net Income(TTM)-288.28M
Analysts81.67
Price Target662.36 (50.54%)
Short Float %19%
Short Ratio12.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-203.8%
Min EPS beat(2)-274%
Max EPS beat(2)-133.61%
EPS beat(4)2
Avg EPS beat(4)-86.34%
Min EPS beat(4)-274%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)-35.67%
EPS beat(12)6
Avg EPS beat(12)-23.45%
EPS beat(16)7
Avg EPS beat(16)-18.84%
Revenue beat(2)2
Avg Revenue beat(2)7.31%
Min Revenue beat(2)0.74%
Max Revenue beat(2)13.88%
Revenue beat(4)4
Avg Revenue beat(4)15.34%
Min Revenue beat(4)0.74%
Max Revenue beat(4)28.53%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.92%
PT rev (3m)29.92%
EPS NQ rev (1m)12.8%
EPS NQ rev (3m)47.32%
EPS NY rev (1m)-1.6%
EPS NY rev (3m)-14.43%
Revenue NQ rev (1m)0.72%
Revenue NQ rev (3m)0.27%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)8.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 418.19
P/S 10.43
P/FCF N/A
P/OCF N/A
P/B 16.58
P/tB 16.79
EV/EBITDA N/A
EPS(TTM)-12.75
EYN/A
EPS(NY)1.05
Fwd EY0.24%
FCF(TTM)-8.5
FCFYN/A
OCF(TTM)-8.35
OCFYN/A
SpS42.2
BVpS26.54
TBVpS26.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.89%
ROE -47.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.14%
FCFM N/A
ROA(3y)-41.97%
ROA(5y)-59.17%
ROE(3y)-67.26%
ROE(5y)-94.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 230.21%
Cap/Sales 0.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.01
Quick Ratio 3.77
Altman-Z 7.62
F-Score3
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)366.82%
Cap/Depr(5y)239.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.17%
EPS Next Y108.25%
EPS Next 2Y84.4%
EPS Next 3Y70.98%
EPS Next 5Y51.42%
Revenue 1Y (TTM)432.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%210.77%
Revenue Next Year53.11%
Revenue Next 2Y49.37%
Revenue Next 3Y45.61%
Revenue Next 5Y38.52%
EBIT growth 1Y39.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.22%
EBIT Next 3Y77.55%
EBIT Next 5YN/A
FCF growth 1Y58.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.39%
OCF growth 3YN/A
OCF growth 5YN/A

MADRIGAL PHARMACEUTICALS INC / MDGL FAQ

What is the ChartMill fundamental rating of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MDGL.


What is the valuation status for MDGL stock?

ChartMill assigns a valuation rating of 2 / 10 to MADRIGAL PHARMACEUTICALS INC (MDGL). This can be considered as Overvalued.


Can you provide the profitability details for MADRIGAL PHARMACEUTICALS INC?

MADRIGAL PHARMACEUTICALS INC (MDGL) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MADRIGAL PHARMACEUTICALS INC?

The Earnings per Share (EPS) of MADRIGAL PHARMACEUTICALS INC (MDGL) is expected to grow by 108.25% in the next year.